Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a two arm, randomized, phase II study of patients with advanced KRAS mutation
positive and PD-L1 high NSCLC who have not received therapy for advanced stage disease.
Patients will be randomized between Arm A and Arm B treatment. Arm A treatment will consist
of durvalumab every 4 weeks for 13 cycles. Arm B treatment will consist of durvalumab with
chemotherapy every 3 weeks for 4 cycles followed by durvalumab with pemetrexed every 3 weeks
for 13 cycles.